Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab / Lauterio, A.; Valsecchi, M.; Santambrogio, S.; De Carlis, R.; Merli, M.; Calini, A.; Centonze, L.; Buscemi, V.; Bottiroli, M.; Puoti, M.; Fumagalli, R.; De Carlis, L.. - In: TRANSPLANT INFECTIOUS DISEASE. - ISSN 1398-2273. - 22:5(2020), pp. 1-5. [10.1111/tid.13334]
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab
Centonze L.;
2020
Abstract
Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.
| File | Dimensione | Formato | |
|---|---|---|---|
|
18-2020.Successful_Recovery_From_COVID-19_Pneumonia_After_Kidney_Transplantation_The_Interplay_Between_Immunosuppression_and_Novel_Therapy_Including_Tolicizumab.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
764.37 kB
Formato
Adobe PDF
|
764.37 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
